Envista Holdings Corporation
NYQ: NVSTLive Quote
📈 ZcoreAI Score
Our AI model analyzes Envista Holdings Corporation's price action across multiple timeframes using regression channels and statistical scoring.
Get NVST Z-Score →About Envista Holdings Corporation
Healthcare
Medical Instruments & Supplies
Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products, as well as provides DTX Studio Clinic, a software package offered with its imaging products. This segment offers its products under the Nobel Biocare, Alpha-Bio Tec, Implant Direct, Nobel Procera, Ormco, Spark, Orascoptic, Damon, Insignia, AOA brands. The Equipment & Consumables segment provides dental equipment and supplies, including digital imaging systems, software, and other visualization/magnification systems; endodontic systems and related products; restorative materials, rotary burs, impression materials, bonding agents, and cements; and infection prevention products. This segment offers its products under the Dexis, DTX Studio, Kerr, Metrex, Total Care, Pentron, Optibond, Harmonize, Sonicfill, Sybron Endo, and CaviWipes to dental offices, clinics, and hospitals. Envista Holdings Corporation was incorporated in 2018 and is headquartered in Brea, California.
📊 Fundamental Analysis
Envista Holdings Corporation demonstrates a profit margin of 1.7%, which is below the sector average, suggesting competitive pressure.
The company recently reported 15.0% revenue growth, which is above average for the Healthcare sector.
Return on Equity (ROE) is 1.6%, which suggests room for improvement in capital utilization.
At a current price of $26.39, NVST currently sits at the 74th percentile of its 52-week range (Range: $14.72 - $30.42).
💰 Valuation Insight
NVST trades at a 277.0% premium to the sector average PE of 25.00. Analysts expect earnings growth, as indicated by a lower forward PE.
🏥 Financial Health
🔴
Profit Margin
Weak
⚠️
Debt/Equity
Moderate
✅
Revenue Growth
Excellent
🔴
Return on Equity
Weak
⚠️
Beta (Risk)
Moderate Volatility
Key Financials
Market Cap
$4.32B
Trailing P/E
94.25
Forward P/E
16.93
Beta (5Y)
0.98
52W High
$30.42
52W Low
$14.72
Avg Volume
2.93M
Day High
Day Low